ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Cytomeglovirus"

  • 2022 American Transplant Congress

    Preemptive  Therapy for Cytomegalovirus (CMV) Disease Prevention in High-Risk CMV Donor Seropositive Recipient Seronegative (D+/R-) Liver Transplant Recipients in a Real-World Setting 

    K. M. Doss1, C. Kling1, M. R. Heldman1, N. Singh2, M. Wagener3, C. E. Fisher1, A. Limaye1

    1University of Washington, Seattle, WA, 2University of Pittsburgh, PIttsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA

    *Purpose:  Preemptive therapy  (PET)  has  demonstrated superiority to antiviral prophylaxis  for  prevention of  cytomegalovirus (CMV)  disease  in  CMV  donor seropositive/recipient seronegative (D+R-)  liver transplant recipients …
  • 2022 American Transplant Congress

    Multidimensional Immunological Profiling of CMV Dnaemia in Kidney Transplant Recipients

    H. Pickering1, S. Sen2, R. S. Ahn2, Z. Qian1, G. Sunga1, M. LLamas1, A. Hoffmann1, M. Deng1, S. Bunnapradist3, J. Schaenman4, D. W. Gjertson1, M. Rossetti1, E. Reed5

    1UCLA, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA, 3David Geffen School of Medicine, Los Angeles, CA, 4David Geffen School of Medicine at UCLA, Los Angeles, CA, 5Univ of California LA, Los Angeles, CA

    *Purpose: Human cytomegalovirus (CMV) infects over half the global population, leading to a mostly asymptomatic but lifelong infection. Primary infection or reactivation in immunocompromised individuals…
  • 2022 American Transplant Congress

    Incidence of Viral Infections in Kidney Transplant Recipients Using Reduced Induction and Steroid Free Maintenance Immunosuppression

    P. Dunton, L. Von Stein, H. Winters, A. Schenk, T. Pesavento, R. M. Smith, K. Schnelle

    Ohio State University Wexner Medical Center, Columbus, OH

    *Purpose: Viral infections (VI) commonly occur in the post-transplant period and higher cumulative doses of rATG have been correlated with higher rates of infection. However,…
  • 2022 American Transplant Congress

    Single Dose Alemtuzemab Provides Comparable Rejection Free and Infection Free Survival Compared to Double Dose Alemtuzumab. In Comparison to Alemtuzemab, Basiliximab Has Superior Infection Free Graft Survival. Results from a Steroid Sparing Transplant Group

    H. Sharma, A. Odugoudar, B. Devkaran, A. Rao, A. El-Bakry, T. Gunawardhane, D. Ridgway, M. Howse, S. Mehra

    Department of Transplant Surgery, Royal Liverpool University Hospital, Liverpool, United Kingdom

    *Purpose: The present study investigated the short-term biopsy-proven acute rejection rates and viral infection rates amongst our protocol of single-dose Alemtuzemab (Cohort 1) versus double…
  • 2022 American Transplant Congress

    Cytomegalovirus Prevention in Kidney and Pancreas Transplant Recipients: A Successful Pharmacist-Led Multidisciplinary Approach

    J. Geyston, J. Dann, A. Doyle, A. Agarwal, K. Brayman, C. Shoemaker, C. Lester, S. Rao

    University of Virginia Health, Charlottesville, VA

    *Purpose: In response to high cytomegalovirus (CMV) infection and increasing ganciclovir (GCV)-resistance rate, a pharmacist-led multidisciplinary task force was created to manage CMV prophylaxis (ppx).…
  • 2022 American Transplant Congress

    Early versus Delayed Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

    A. Hutchins1, M. Leick2, M. Keck2, J. S. McMullen2

    1Pharmacy, Houston Methodist Hospital, Houston, TX, 2Pharmacy, Nebraska Medicine, Omaha, NE

    *Purpose: The purpose of this study is to determine the effect of delaying cytomegalovirus (CMV) prophylaxis to day of discharge or post-operative day (POD) 7…
  • 2022 American Transplant Congress

    De-Novo Belatacept Therapy is Associated with an Increased Risk of Invasive CMV Disease After Kidney Transplantation

    G. Petrossian1, J. Ortiz2, K. Addonizio1, A. Hsiao1, L. Teixeira1, N. Koizumi3, R. James3, S. Patel4, D. Conti2, R. Plews2

    1Albany Medical Center, Albany, NY, 2Division of Renal and Pancreatic Transplant Services, Albany Medical Center, Albany, NY, 3George Mason University, Fairfax, VA, 4UMC Las Vegas, Las Vegas, NV

    *Purpose: To compare the rate of CMV viremia and invasive disease in kidney transplantation patients with a de-novo belatacept (bela) regimen vs. a no-bela maintenance…
  • 2022 American Transplant Congress

    Recurrent Cytomegalovirus and the Role of Secondary Prophylaxis in Heart and Lung Transplant Recipients

    S. N. Finder1, K. Harrison1, M. Morrison1, S. Rega2, I. Feurer2, C. Gorsline3, G. Satyanarayana3, S. Hamel1

    1Department of Pharmaceutical Sciences, Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt Transplant Center, Nashville, TN, 3Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN

    *Purpose: This study aimed to describe the incidence of cytomegalovirus (CMV) recurrence in heart and lung transplant recipients and the effect of secondary prophylaxis (SP)…
  • 2022 American Transplant Congress

    Valganciclovir for the Prevention of CMV After Treatment of Rejection with Anti-Lymphocyte Depleting Antibodies in Kidney Transplant Recipients

    M. Mahoney, J. Nelson, E. Kincaide, R. Hall, H. Sweiss

    University Health, San Antonio, TX

    *Purpose: To evaluate efficacy and safety of valganciclovir for prevention of cytomegalovirus (CMV) after treatment of rejection with anti-lymphocyte depleting antibodies (ALA).*Methods: This single-center retrospective…
  • 2022 American Transplant Congress

    Detection of CMV Mediated Sub-Clinical Rejection by Urine Biomarkers

    S. Ghosh1, R. Sarwal1, C. Mark1, E. Reed2, J. Shoji3, S. Bunnapradist2, T. Sigdel3, M. Sarwal3

    1Nephrosant Inc, San Francisco, CA, 2UCLA, Los Angeles, CA, 3UCSF, San Francisco, CA

    *Purpose: Research on early detection of Cytomegalovirus (CMV) mediated sub-clinical rejection (sAR) is in its nascence. This study explores the efficacy of urine-based biomarkers for…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 33
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences